|
Prior to joining OVATION Pharmaceuticals in 2008, Dr. Chris Silber was Executive Medical Director and Global Development Team Leader for Takeda's diabetic neuropathy and neuropathic pain clinical programs. Previously, Dr. Silber led drug development and medical services for Hospira's critical care and generics portfolios. This followed 13 years at Abbott Laboratories where he served in a variety of leadership roles in clinical neuroscience drug development as Venture Head in analgesia and psychopharmacology. His responsibilities included extensive early stage new chemical entity (NCE) research as well as oversight of late stage clinical programs. He began his career in industry at Forest Laboratories as a medical monitor for clinical trials in Alzheimer's Disease. | 